STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultMay 13, 2026, 08:22 AM

QT Imaging Q1 Revenue $6.5M, Loan Extended, CPT Code Secured

AI Summary

QT Imaging Holdings, Inc. announced its first quarter 2026 financial results, reporting a significant 133% year-over-year revenue increase to $6.5 million, driven by increased scanner shipments. The company also reduced its net loss to $3.4 million from $11.1 million in the prior year. Key business achievements include securing a Category III CPT code for its technology, extending its senior secured term loan, and receiving FDA clearance for product enhancements, alongside international expansion in the UAE.

Key Highlights

  • QT Imaging reported Q1 2026 revenue of $6.5 million, a 133% increase from $2.8 million in Q1 2025.
  • Net loss for Q1 2026 was $3.4 million, or $0.25 per share, compared to $11.1 million, or $1.21 per share, in Q1 2025.
  • The company shipped 13 Breast Acoustic CT scanners in Q1 2026, up from six in the prior-year period.
  • Secured a Category III CPT code (X579T) for its 3D breast imaging technology, effective January 1, 2027.
  • Extended the maturity date of its senior secured term loan by two years to March 31, 2029.
  • Received FDA 510(k) clearance for enhancements to improve visualization of posterior breast tissue.
  • Expanded internationally with regulatory clearance in the UAE, supporting a multiyear commercial agreement for over $24 million in revenue.
  • Reaffirmed 2026 revenue guidance of approximately $39 million.
QTI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
QT IMAGING HOLDINGS, INC.

Price Impact